Madrigal Pharmaceuticals (MDGL) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to -$2.0 billion.
- Madrigal Pharmaceuticals' Retained Earnings fell 1658.82% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 1658.82%. This contributed to the annual value of -$1.8 billion for FY2024, which is 3486.36% down from last year.
- According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Retained Earnings is -$2.0 billion, which was down 1658.82% from -$1.9 billion recorded in Q2 2025.
- Madrigal Pharmaceuticals' 5-year Retained Earnings high stood at -$478.0 million for Q1 2021, and its period low was -$2.0 billion during Q3 2025.
- Over the past 5 years, Madrigal Pharmaceuticals' median Retained Earnings value was -$1.1 billion (recorded in 2023), while the average stood at -$1.2 billion.
- As far as peak fluctuations go, Madrigal Pharmaceuticals' Retained Earnings plummeted by 8427.53% in 2021, and later crashed by 1658.82% in 2025.
- Madrigal Pharmaceuticals' Retained Earnings (Quarter) stood at -$667.3 million in 2021, then plummeted by 44.27% to -$962.7 million in 2022, then tumbled by 38.81% to -$1.3 billion in 2023, then crashed by 34.86% to -$1.8 billion in 2024, then fell by 12.75% to -$2.0 billion in 2025.
- Its Retained Earnings stands at -$2.0 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.9 billion for Q1 2025.